ArticleArchives of medical science : AMS2026
Metabolic insights into metabolic dysfunction-associated steatotic liver disease: the impact of gut microbiota and TCM constitutions.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is intricately linked to gut microbiota dysbiosis and has been associated with different traditional Chinese medicine (TCM) constitution types. This study explored the fecal microbiota composition in MASLD patients to investigate the associations underlying the disease. Material and methods: In this study, 51 MASLD patients and 46 healthy controls were classified into seven TCM constitution groups based on high-throughput sequencing of fecal samples. Analyses were conducted to compare microbial communities, metabolite profiles, and metabolic pathways among these constitution groups. The relationships between specific microbiota and biochemical indicators were evaluated using linear discriminant analysis (LDA) effect size (LEfSe) and Spearman correlation analyses. Results: MASLD patients exhibited reduced fecal microbiota diversity compared to healthy controls, with significant variations in microbial structure among TCM constitution groups. The damp-heat constitution (DHC) and phlegm-dampness constitution (PDC) groups displayed enriched populations of specific microbial species, distinct bacterial taxa, and unique metabolite profiles. Multiple significant pathways related to amino acid, fatty acid, and carbohydrate metabolism were identified through metabolic pathway enrichment analysis. Significant correlations were observed between specific microbial taxa and biochemical indicators such as triglycerides, total cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Conclusions: This study highlights the close association between alterations in gut microbiota, TCM constitution differences, and MASLD progression. The findings suggest that changes in microbial diversity and metabolite profiles may contribute to MASLD pathogenesis. The identification of constitution-specific microbial may provide insights into personalized intervention strategies for MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.